<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04935931</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001668</org_study_id>
    <nct_id>NCT04935931</nct_id>
  </id_info>
  <brief_title>Naltrexone Neuroimaging</brief_title>
  <acronym>EDIT-N2</acronym>
  <official_title>Eating Disorder Individualized Therapeutics-Naltrexone Neuroimaging (EDIT-N2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Mercy Hospital Kansas City</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open-label, pilot study is to evaluate fMRI as a biomarker of opioid&#xD;
      antagonism in adolescents with ED. Modulation of brain activation will be examined in regions&#xD;
      of interest by fMRI using a food-specific and general reward task in adolescents with ED in a&#xD;
      pre/post design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, interventional trial to evaluate reward system modulation (detected by&#xD;
      neuroimaging) in response to opioid antagonism (i.e., naltrexone) in adolescents aged 13-21&#xD;
      years with an eating disorder characterized by the target behaviors of binge eating and/or&#xD;
      purging (e.g., AN-BP, BN, BED). A pre/post design completed on the same day will be employed&#xD;
      to quantify within-individual change while reducing potential confounding due to known&#xD;
      neuroimaging variables (e.g., menstrual phase, treatment changes) that may occur with time&#xD;
      elapsed between study visits. Self-report data regarding will be captured via electronic&#xD;
      surveys using validated instruments (where possible), structured interview, study records.&#xD;
&#xD;
      Reward System Modulation by fMRI. Each scan will last approximately 1 hour and involve two&#xD;
      reward activation paradigms: passive food view (PFV) and monetary incentive delay (MID).&#xD;
      These two reward activation paradigms provide distinct insight and will generate pilot data&#xD;
      to support the choice of the optimal paradigm for further testing of reward system modulation&#xD;
      in adolescents with eating disorders. PFV provides a paradigm that is relevant to the target&#xD;
      behaviors (i.e., binge eating, purging), has been evaluated in ED patients, in response to&#xD;
      naltrexone in adults, and is expected to activate food cue-reactivity regions (e.g.,&#xD;
      prefrontal cortex). MID is a widely used paradigm in adolescents to detect reward&#xD;
      anticipation and receipt particularly in the striatum and is currently being used to study&#xD;
      the developmental trajectory of reward processing in the longitudinal Adolescent Brain&#xD;
      Cognitive Development (ABCD) trial. To the greatest extent possible, we will harmonize our&#xD;
      fMRI parameters with those published for ABCD.&#xD;
&#xD;
      Opioid Antagonism and exposure-response linkage. A single oral dose of naltrexone&#xD;
      hydrochloride 50 mg tablet will be administered. Plasma and urine will be obtained to measure&#xD;
      systemic exposure to naltrexone and it primary, active metabolite, 6-beta-naltrexol, using a&#xD;
      validated UPLC-MS/MS assay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% Blood oxygenation level dependent change (%BOLD)</measure>
    <time_frame>Study day 1</time_frame>
    <description>MRI to detect %BOLD changes pre- and post-opioid antagonist treatment (i.e., naltrexone) within individuals during a food reward and general reward task using regions of interest (ROI) analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Region of interest (ROI)</measure>
    <time_frame>Study day 1</time_frame>
    <description>Coordinates with largest %BOLD change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optimal reward paradigm</measure>
    <time_frame>Study day 1</time_frame>
    <description>Paradigm (e.g., PFV or MID) resulting in largest %BOLD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure</measure>
    <time_frame>Study day 1</time_frame>
    <description>Maximum plasma concentration of naltrexone</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Eating Disorders</condition>
  <condition>Binge Eating</condition>
  <condition>Purging (Eating Disorders)</condition>
  <arm_group>
    <arm_group_label>Pilot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre/post fMRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>naltrexone 50 mg PO x 1</description>
    <arm_group_label>Pilot</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eating disorder diagnosis per DSM-V criteria that is characterized by binge eating&#xD;
             (defined as loss of control of eating resulting in large amount of food consumed in a&#xD;
             short period of time) and/or purging (e.g., vomiting, excessive exercising, laxative&#xD;
             use)&#xD;
&#xD;
          -  Stable medication regimen (no dose or drug changes in the past 4 weeks)&#xD;
&#xD;
          -  Participant and parent/legal guardian (if under 18 years) are willing and able to&#xD;
             provide informed permission/assent/consent for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant (via UCG)&#xD;
&#xD;
          -  Prior hypersensitivity reaction to naltrexone (e.g., anaphylaxis)&#xD;
&#xD;
          -  Non-removable metal in the body&#xD;
&#xD;
          -  Current naltrexone use&#xD;
&#xD;
          -  Self-reported opioid use in the past 7 days&#xD;
&#xD;
          -  A language barrier (e.g., non-English speaking) for the participant that precludes&#xD;
             communication and/or ability to complete all study-related requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Mercy Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Frazier</last_name>
      <phone>816-234-3000</phone>
      <email>rsfrazier@cmh.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ileana Cepeda</last_name>
      <phone>816-234-3000</phone>
      <email>iecepeda@cmh.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephani L Stancil, PhD, APRN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Mercy Hospital Kansas City</investigator_affiliation>
    <investigator_full_name>Stephani Stancil</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Adolescent</keyword>
  <keyword>Eating Disorder</keyword>
  <keyword>Neuroimaging</keyword>
  <keyword>Naltrexone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

